Clinical Trial Update: An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc at Steady State Following Once-daily Administration of CASSIPA® in Opioid Dependent Subjects. [Phase 4]

View source ↗

Summary

An open-label Phase 4 trial evaluating exposure–response for QTc changes with once-daily CASSIPA in opioid-dependent subjects was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Dependence
• Opioid Use Disorder

Drugs mentioned

• CASSIPA

Snippet

Sponsor: Teva Pharmaceuticals USA | Conditions: Evaluation of QTc Interval | Phase 4 | Status: WITHDRAWN